Canopy Growth (CGC) vs Emergent BioSolutions (EBS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Emergent BioSolutions (EBS) has outperformed Canopy Growth (CGC) over the past year, losing 28.7% versus a loss of 39.6%. Over five years, EBS leads with a -86.1% price change compared with -99.3% for CGC. Canopy Growth is the larger company by market cap ($393.8 million vs $362.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | EBS |
|---|---|---|
| Share price | $0.8765 | $7.07 |
| Market cap | $393.81M | $362.50M |
| 1-day change | -1.59% | +1.73% |
| YTD return | -23.11% | -42.80% |
| 1-year return | -39.55% | -28.73% |
| 5-year return | -99.34% | -86.05% |
| Forward P/E | — | 6.76 |
| EPS (TTM) | $-0.45 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $14.06 |
| 52-week low | $0.844 | $4.36 |
| Distance from 52-week high | -63.17% | -49.72% |
| Analyst consensus | none | none |
| Avg. price target upside | +35.77% | +55.59% |
| Average volume | 2.77M | 1.16M |
| Shares outstanding | 423.04M | 51.27M |
| Employees | 1,128 | 900 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EBS has outperformed CGC by 10.8 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,128 employees
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Healthcare · Drug Manufacturers - Specialty & Generic · 900 employees
CGC vs EBS FAQ
Which is bigger, Canopy Growth or Emergent BioSolutions?
Canopy Growth (CGC) is larger, with a market capitalization of $393.81M compared with $362.50M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, CGC or EBS?
EBS returned -28.73% over the past 12 months, compared with -39.55% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Emergent BioSolutions in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.